Yutong Jiang

USPTO Granted Patents = 68 (Patent Applications = 11)

CIPO Patents = 15 (Patent Applications = 5)

EPO Patents = 19 (Patent Applications = 27)

Average Co-Inventor Count = 7.1

ph-index = 18

Forward Citations = 955(Granted Patents)

Forward Citations (Not Self Cited) = 490(Oct 12, 2025)

Inventors with similar research interests:

Location History:

Longmont, CO (US) (2009 - 2024)
Boulder, CO (US) (2013 - 2024)
Indianapolis, IN (US) (2024)

Company Filing History:

Eli Lilly and Company

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

68 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),

2. 11964988 - Fused heterocyclic compounds as RET kinase inhibitors (2024-04-23),

3. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

4. 11851434 - Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors (2023-12-26),

5. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),

6. 11634417 - Protein tyrosine phosphatase inhibitors (2023-04-25),

7. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),

8. 11524963 - Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors (2022-12-13),

9. 11472802 - Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors (2022-10-18),

10. 11267818 - Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds (2022-03-08),

11. 11214571 - Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof (2022-01-04),

12. 11168090 - Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors (2021-11-09),

13. 11091486 - Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof (2021-08-17),

14. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),

15. 10889589 - Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain (2021-01-12),

Title: Yutong Jiang: A Pioneering Innovator in RET Kinase Inhibitors

Introduction

Yutong Jiang is a remarkable inventor based in Boulder, Colorado, holding an impressive portfolio of 68 patents. His innovative contributions primarily focus on compounds that serve as RET kinase inhibitors, which have significant implications for treating various RET-associated diseases and disorders.

Latest Patents

Among Yutong Jiang's latest patents are two noteworthy innovations. The first is titled "Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors." This patent describes compounds that are designed to inhibit RET kinase, providing potential treatment options for diseases related to RET dysregulation. The second patent, "Fused heterocyclic compounds as RET kinase inhibitors," presents additional compounds that maintain the same goal, enhancing therapeutic possibilities for conditions associated with RET kinase activity.

Career Highlights

Yutong Jiang's professional journey includes vital roles at recognized companies such as Array Biopharma Inc. and Intermune, Inc. At these organizations, he harnessed his expertise in medicinal chemistry and drug design to advance innovative solutions in pharmaceuticals. His work has significantly contributed to the field, particularly concerning targeted therapies for complex diseases.

Collaborations

Throughout his career, Jiang has collaborated with talented professionals, including Julia Haas and Steven Wade Andrews. These partnerships have fostered a collaborative environment, enriching the inventive process and leading to significant advancements in the realm of RET kinase inhibitors.

Conclusion

Yutong Jiang's dedication to innovation in the field of medicinal chemistry is evident through his extensive patent portfolio and impactful collaborations. His contributions to the development of RET kinase inhibitors promise to expand therapeutic options for patients, showcasing the power of innovation in the fight against challenging diseases.

This text is generated by artificial intelligence and may not be accurate.